Peripheral compartment innate immune response to Haemophilus influenzae and Streptococcus pneumoniae in chronic obstructive pulmonary disease patients

Innate Immunity

Volumn 19, Issue 4, 2013, Pages 428-437

  Francis, Santiyagu M Savarimuthu ^a,b   Tan, Maxine E ^a   Fung, Pamela R ^b   Shaw, Janet G ^a,b   Semmler, Annalese B T ^c   Nataatmadja, Maria ^b   Bowman, Rayleen V ^a,b   Fong, Kwun M ^a,b   Yang, Ian A ^a,b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Chronic obstructive pulmonary disease; decline; FEV1; innate immunity; lung function

Indexed keywords

CD14 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE SEVERITY; DOWN REGULATION; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LEUKOCYTE COUNT; LUNG FUNCTION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SMOKING; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UPREGULATION;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; DECLINE; FEV1; INNATE IMMUNITY; LUNG FUNCTION;

AGED; AGED, 80 AND OVER; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 84880278320     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425912466926     Document Type: Article

References (46)

1. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010 ; 363: 1128-1138
2. Reddel HK, Upham JW, Salvi SS, Yang IA. Year-in-review 2009: Asthma, COPD and airway biology. Respirology. 2010 ; 15: 365-376
3. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med. 2002 ; 96: 700-708
4. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest. 2007 ; 131: 696-704
5. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011 ; 365: 1184-1192
6. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011 ; 184: 662-671
7. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS ONE. 2011 ; 6: e16384 - e16384
8. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med. 2000 ; 109: 288-295
9. Moghaddam SJ, Ochoa CE, Sethi S, Dickey BF. Nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease and lung cancer. Int J Chron Obstruct Pulmon Dis. 2011 ; 6: 113-123
10. Kersul AL, Iglesias A, Rios A, et al. Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol. 2011 ; 47: 176-183
11. Bathoorn E, Kerstjens H, Postma D, et al. Airways inflammation and treatment during acute exacerbations of COPD. Int J Chronic Obstruct Pulmon Dis. 2008 ; 3: 217-229
12. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011 ; 378: 1015-1026
13. Green RM, Gally F, Keeney JG, et al. Impact of cigarette smoke exposure on innate immunity: a Caenorhabditis elegans model. PLoS ONE. 2009 ; 4: e6860 - e6860
14. Garmendia J, Morey P, Bengoechea JA. Impact of cigarette smoke exposure on host-bacterial pathogen interactions. Eur Respir J. 2012 ; 39: 467-477
15. World Health Organization (WHO). Global strategy for the diagnosis, management, and prevention of chronic obstructive pumonary disease. Geneva: WHO, 2011
16. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005 ; 26: 319-338
17. Yang IA, Seeney SL, Wolter JM, et al. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun. 2003 ; 4: 269-274
18. Oh H, Siano B, Diamond S. Neutrophil isolation protocol. J Vis Exp. 2008 ; 23: 745-745
19. Caramori G, Romagnoli M, Casolari P, et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax. 2003 ; 58: 348-351
20. Mercer PF, Shute JK, Bhowmik A, et al. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res. 2005 ; 6: 151-151
21. Lucas M, Stuart LM, Savill J, Lacy-Hulbert A. Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J Immunol. 2003 ; 171: 2610-2615
22. van Furth AM, Verhard-Seijmonsbergen EM, Langermans JA, et al. Anti-CD14 monoclonal antibodies inhibit the production of tumor necrosis factor alpha and interleukin-10 by human monocytes stimulated with killed and live Haemophilus influenzae or Streptococcus pneumoniae organisms. Infect Immun. 1999 ; 67: 3714-3718
23. Mogensen TH, Paludan SR, Kilian M, Ostergaard L. Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J Leukoc Biol. 2006 ; 80: 267-277
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001 ; 29: e45 - e45
25. Taylor AE, Finney-Hayward TK, Quint JK, et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J. 2010 ; 35: 1039-1047
26. Tietze K, Dalpke A, Morath S, et al. Differences in innate immune responses upon stimulation with gram-positive and gram-negative bacteria. J Periodontal Res. 2006 ; 41: 447-454
27. Feezor RJ, Oberholzer C, Baker HV, et al. Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria. Infect Immun. 2003 ; 71: 5803-5813
28. Boldrick JC, Alizadeh AA, Diehn M, et al. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci USA. 2002 ; 99: 972-977
29. DeChatelet LR, Mullikin D, Shirley PS, McCall CE. Phagocytosis of live versus heat-killed bacteria by human polymorphonuclear leukocytes. Infect Immun. 1974 ; 10: 25-29
30. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 ; 163: 349-355
31. Calikoglu M, Sahin G, Unlu A, et al. Leptin and TNF-alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters. Respiration. 2004 ; 71: 45-50
32. Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006 ; 3: 245-251
33. Antoniu SA, Mihaltan F, Ulmeanu R. Anti-TNF-alpha therapies in chronic obstructive pulmonary diseases. Expert Opin Investig Drugs. 2008 ; 17: 1203-1211
34. Pons J, Sauleda J, Regueiro V, et al. Expression of Toll-like receptor 2 is up-regulated in monocytes from patients with chronic obstructive pulmonary disease. Respir Res. 2006 ; 7: 64-64
35. Sahlander K, Larsson K, Palmberg L. Altered innate immune response in farmers and smokers. Innate Immun. 2010 ; 16: 27-38
36. Baines KJ, Simpson JL, Gibson PG. Innate immune responses are increased in chronic obstructive pulmonary disease. PLoS ONE. 2011 ; 6: e18426 - e18426
37. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005 ; 128: 1995-2004
38. Aldonyte R, Jansson L, Piitulainen E, Janciauskiene S. Circulating monocytes from healthy individuals and COPD patients. Respir Res. 2003 ; 4: 11-11
39. Yanbaeva DG, Dentener MA, Spruit MA, et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. BMC Med Genet. 2009 ; 10: 23-23
40. de Godoy I, Donahoe M, Calhoun WJ, et al. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med. 1996 ; 153: 633-637
41. Larsen JM, Steen-Jensen DB, Laursen JM, et al. Divergent pro-inflammatory profile of human dendritic cells in response to commensal and pathogenic bacteria associated with the airway microbiota. PLoS ONE. 2012 ; 7: e31976 - e31976
42. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007 ; 356: 775-789
43. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009 ; 374: 1171-1178
44. Blidberg K, Palmberg L, Dahlén B, et al. Chemokine release by neutrophils in chronic obstructive pulmonary disease. Innate Immunity. 2012 ; 18: 503-510
45. Berenson CS, Wrona CT, Grove LJ, et al. Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006 ; 174: 31-40
46. Poliska S, Csanky E, Szanto A, et al. Chronic obstructive pulmonary disease-specific gene expression signatures of alveolar macrophages as well as peripheral blood monocytes overlap and correlate with lung function. Respiration. 2011 ; 81: 499-510